fpl 52757 has been researched along with levofloxacin in 1 studies
| Studies (fpl 52757) | Trials (fpl 52757) | Recent Studies (post-2010) (fpl 52757) | Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) |
|---|---|---|---|---|---|
| 6 | 2 | 1 | 4,346 | 581 | 2,209 |
| Protein | Taxonomy | fpl 52757 (IC50) | levofloxacin (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 7.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for fpl 52757 and levofloxacin
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |